Sir,

Owing to the increased rate of resistance among the *Helicobacter pylori* strains, the efficacy of the prescribed antibiotics has reduced globally.\[[@ref1]\] Consequently, alternative approaches can be an option to overcome this unsolved issue in clinical trials.\[[@ref2]\] Probiotics, as a living bacterium in gastrointestinal routes, which provides health benefits has been called as a potential candidate. Recently, several studies investigated the efficacy of different probiotics in experimental and large scale levels. Recently, Dajani *et al*., proposed *Bifidobacterium infantis* as a preferable adjuvant for several therapeutic regimens used to eradicate the *H. pylori* infection.\[[@ref3]\] Although probiotic therapy as an adjuvant had been reported to be an effective approach for treatment of *H. pylori*, the exact mechanism is not clearly elucidated yet. Moreover, the success of each of the three investigated therapeutic regimens in study by Dajani *et al*., need to be evaluated separately.\[[@ref2]\] In other words, prescription of probiotic (*B. infantis*) in *H. pylori* therapeutic regimens should be compared with particular negative control group. In other words, adding a probiotic (*B. infantis*) should be recommended under assumption of independent factors, including various treatment regimens. Altogether, the current findings should be recommended to clinicians with caution. Meanwhile, the current data by Dajani *et al*., can be a good pilot, which will be encouraging for other groups in the aforementioned area to disclose further interesting findings for drawing a comprehensive conclusion.
